General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content


Novartis was the first pharmaceutical company with a global leadership position in both patented prescription and generic pharmaceuticals.

Sandoz plays a critical role in the Novartis strategy of offering a complete range of treatment options to patients, physicians and healthcare providers worldwide. This broad portfolio helps to make affordable, high-quality medicines available to patients world-wide and helps stabilize healthcare systems around the world as governments face increasing cost containment pressures.

Two main elements empower the Sandoz business strategy:

  • Global reach and reputation: In addition to its unique position within Novartis, Sandoz benefits from a strong global presence and powerful brand recognition worldwide.
  • Unique expertise: Sandoz distinguishes itself primarily through its ability to develop, produce and commercialize differentiated medicines. Sandoz is the pioneer and global leader of biosimilars — follow-on versions of biopharmaceuticals following patent expiry — with the first three approved and marketed products in the EU (human growth hormone Omnitrope, anemia medicine Binocrit, and oncology medicine Zarzio).

Sandoz - adding value through key differentiated pillars

Sandoz differentiates itself through its ability to develop, produce and commercialize complex, value-added products. The company specializes in complex, differentiated products with a focus on biosimilars, injectables, inhalables, ophthalmics, dermatology, dermatology, anti-infectives and other difficult-to-make generics.

For additional information please roll-over the Sandoz graphic below.


High-quality, clinically-proven alternatives to existing biologics which offer comparable safety and efficacy at a more affordable price. Sandoz pioneered and clearly leads the way in this field with three marketed biosimilars. This accounts for approximately half of the total biosimilar market segment in the combined markets of the US, Canada, EU, Japan and Australia.